Greystone Housing Impact Investors LP (NYSE:GHI) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsJeffrey Neal - Investment AdviserJesse Coury - CFOJonathan Baum - ShareholderKen Rogozinski - Chief Executive OfficerLarry Linden - ShareholderNathaniel Beam - Investment AdviserConference Call ParticipantsChris Muller - Research AnalystMatthew Erdner - Equity Research AnalystOperatorThe Greystone Housing Impact Investors LP conference call. At this time, all participants are in a listen-onl ...

Financial Data and Key Metrics Changes - In Q3, revenues were $329.1 million, down from $335.4 million in the prior year period, reflecting a decrease of approximately 1% [20] - Adjusted operating loss was $24.3 million compared to $20.9 million in the prior year, while adjusted EBITDA was approximately break even compared to $6 million in the prior year [20] - Net loss was $3.5 million compared to a net loss of $1.3 million in the prior year period, with adjusted loss per diluted share increasing to $0.15 from $0.05 [21] Business Line Data and Key Metrics Changes - Children's Book Publishing and Distribution revenues decreased 3% to $197.6 million, with adjusted operating profit improving to $8.9 million from $7.6 million [21] - Book Fairs revenue increased 2% to $113.3 million, driven by higher revenue per fair, while Book Clubs revenues were relatively flat at $14.6 million [22] - Trade Publishing revenues were $69.7 million, down 10% from $77.4 million, reflecting the timing of major releases [23] - Entertainment segment revenues increased by $3.2 million to $16 million, driven by increased episodic deliveries [23] - Education segment revenues were $56.1 million, down 2% from $57.2 million, but adjusted operating loss improved to $5.2 million from $6.9 million [25] Market Data and Key Metrics Changes - International segment revenues were $58.7 million, down from $59.3 million, with a decline primarily driven by publication timing [26] - Demand for English language learning materials continues to expand globally, representing a long-term opportunity [18] Company Strategy and Development Direction - The company completed sale leaseback transactions generating over $400 million in net proceeds, optimizing the balance sheet and enhancing shareholder value [4] - A new $300 million share repurchase authorization was announced, including a $200 million modified Dutch auction tender offer [5] - The company aims to return to growth in the education segment by fiscal 2027, focusing on aligning products with district and school needs [17] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed fiscal 2026 adjusted EBITDA guidance of $146 million-$156 million, despite the impact of sale leaseback transactions [31] - The company expects a return to profitability in Q4, driven by improved performance in Book Fairs and Education segments [32] - Management expressed confidence in achieving a 2% revenue growth target for Q4, supported by positive trends in Book Fairs and education solutions [37][38] Other Important Information - The company established long-term net leverage targets of 2-2.5 times Adjusted EBITDA, balancing balance sheet strength with growth investments [28] - Free cash flow in Q3 was $407 million, reflecting proceeds from sale leaseback transactions [27] Q&A Session Summary Question: Confidence in achieving 2% growth target for Q4 - Management indicated that Book Fairs are a major factor for revenue growth, with positive initial indications [37] Question: Sales pipeline for education solutions - Management expects strong performance in summer reading and other educational products, with improving sales pipeline each quarter [42] Question: Adjusted EBITDA guidance for Q4 - Management expressed confidence in achieving the guidance due to cost mitigation actions and the typical profitability of Q4 [46] Question: Performance of the entertainment segment - Management noted an increase in green lighting activity and expects steady growth in the entertainment market [48] Question: Revenue guidance adjustment for the year - Management clarified that the adjustment was related to trade dynamics and not solely the education segment [60]

Snail (NasdaqCM:SNAL) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsHai Shi - CEO, Chief Strategy Officer, and Chairman of the BoardHeidy Chow - CFOPeter Kang - Senior Vice President and Director of Business Development and OperationsSteven Shinmachi - Investor RelationsNone - TranslatorConference Call ParticipantsMichael Kupinski - Director of Research and Media and Entertainment Senior Research AnalystOperatorThank you for standing by, and welcome to Snail, Inc.'s Q4 and Full Year 2 ...

Financial Data and Key Metrics Changes - The company reported a net loss of $2.6 million or $0.17 per unit for Q4 2025, with cash available for distribution (CAD) at $2.8 million or $0.12 per unit [11] - The book value per unit as of December 31 was $11.70, with the closing unit price on March 18 at $5.87, reflecting a 50% discount to net book value [14][15] Business Line Data and Key Metrics Changes - The company is focused on exiting market rate multifamily joint venture (JV) equity investments while reallocating capital into tax-exempt Mortgage Revenue Bonds, which are expected to provide stable, tax-advantaged earnings [6][9] - The company currently has eight market rate multifamily JV equity investments that are either in lease-up or stabilized, with increasing occupancy noted [7][8] Market Data and Key Metrics Changes - The U.S. municipal bond market saw a recovery in Q4 2025, with the high-grade index showing a 4.3% return for the year [25] - The 10-year MMD was at 2.76% and the 30-year MMD at 4.24% at year-end, with slight increases noted due to inflation uncertainty [26] Company Strategy and Development Direction - The company is repositioning its investment portfolio to focus on tax-exempt Mortgage Revenue Bonds, which are expected to yield stable returns compared to the uneven returns from JV equity investments [5][6] - The strategy aims to increase the proportion of tax-exempt income allocated to unitholders over the long term [7] Management Comments on Operating Environment and Future Outlook - Management acknowledged that it will take time to transition capital from JV equity investments to Mortgage Revenue Bonds, but expects this will enhance recurring earnings in the long run [9][10] - The company is optimistic about the leasing trends as the spring leasing season approaches, indicating a potential recovery in occupancy rates [33][34] Other Important Information - The company reported unrestricted cash and cash equivalents of $39.5 million and approximately $49.2 million available on secured lines of credit as of December 31 [15] - The company has a significant amount of investments maturing in the first half of 2026, which will provide additional liquidity [15] Q&A Session Summary Question: Can you provide specifics on the $7 million losses and how they will be recovered? - The losses were primarily due to four properties completing construction, leading to depreciation and non-capitalized interest expenses. As occupancy increases, these losses are expected to narrow [30][31] Question: What are the leasing trends expected as spring approaches? - Management noted that the March to June period is traditionally strong for leasing, and they are monitoring trends closely with property management firms [33][34] Question: Will the foreclosure of properties result in a loss in Q1? - Initial basis in the foreclosed properties is estimated at $112-$150 million, and management aims to recover the original basis through effective management [39][40] Question: What is the status of the $4.5 million return of capital? - The return of capital relates to refinancing opportunities that allowed for the return of capital to the company, minimizing capital in the deals [44][45] Question: Why has there been little insider buying despite the stock price decline? - Management explained that trading restrictions limit when insiders can buy shares, and there has been no sale activity, indicating confidence in the company [82][85]

Financial Data and Key Metrics Changes - The company achieved record full-year revenue of $3.9 million, a 20% increase compared to 2024, with fourth quarter revenue of $1.5 million, representing a 92% increase over the prior year period [3][9] - Gross profit for the fourth quarter was $1 million or 69% of revenue, compared to $0.4 million or 46% of revenue in the prior-year quarter, marking a 188% increase and a 23 percentage point improvement in gross margin [10] - Operating expenses totaled $3.9 million for the fourth quarter of 2025, up from $3.5 million in the prior year quarter, while for the full year, operating expenses totaled $15.2 million, compared to $15.5 million in the prior year period [11][12] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by an increase in surgical procedures across both the Catamaran and SImmetry+ platforms, particularly in the second half of 2025, led by new physician users [3][9] - The company hosted 24 physicians in targeted training sessions for both platforms during the fourth quarter, supporting clinical engagement and adoption [4] Market Data and Key Metrics Changes - The company received FDA 510(k) clearance for the next generation SImmetry+ SI joint fusion system, enhancing its ability to serve a broader range of surgeon preferences and patient anatomies [4][7] - The company expanded its intellectual property portfolio, receiving notices of allowance for multiple applications expected to issue in 2026, bringing its global estate to 29 issued U.S. patents and 31 pending applications [7] Company Strategy and Development Direction - The company is committed to advancing its market position with increased adoption across its expanding portfolio, leveraging regulatory and market momentum to drive broader commercial uptake [8] - The focus is on optimizing the cost structure and scaling operations to extend market reach more efficiently, with plans to accelerate revenue growth and deliver sustained value [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet and exceed expectations in 2026, citing strong adoption momentum and an engaged pipeline of products [22][28] - The company aims to address various patient needs and physician preferences with a multi-product portfolio, enhancing its competitive position in the market [33] Other Important Information - The company strengthened its financial position through a $2.85 million PIPE financing and a subsequent private placement of senior convertible notes for gross proceeds of $4.3 million, providing additional runway for commercial and clinical priorities [5][12] Q&A Session Summary Question: How representative is the Q4 operating expense rate for 2026? - Management indicated that the Q4 rate of $3.9 million is a better baseline moving forward into 2026, with some higher integration costs falling out in Q4 [17][18] Question: What is the revenue outlook for 2026 relative to the $6 million run rate? - Management expressed excitement about adoption momentum and the impact of new product launches on revenue growth in 2026, although they do not provide specific projections [19][21][25] Question: What are the key drivers for revenue growth in 2026? - Management highlighted the multi-product portfolio and the commercial expansion as key drivers, with a focus on addressing various patient and physician needs [27][28] Question: How is the launch of SImmetry+ impacting access to physicians? - Management noted that the broader portfolio allows for multiple solutions, opening doors to more physicians and medical centers, with positive feedback on the SImmetry+ technology [32][34]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue grew 12% to a record $6.6 million, and for the full year, revenue increased 13% to $22.7 million, marking another company record [6][23] - Gross margin for Q4 2025 increased to 91.4% compared to 91.1% in Q4 2024, reflecting the strength of the software-driven SaaS model [6][25] - The company achieved annual operating profitability for the first time since going public, with net income of $1.3 million and EPS of $0.06 [7][33] - Adjusted EBITDA for Q4 2025 was a record $1.9 million, and for the full year, it reached $2.6 million, nearly five times the $520,000 reported in 2024 [7][23] Business Line Data and Key Metrics Changes - SaaS revenue for Q4 2025 grew 12% to $6.62 million, representing over 99% of total revenue for the quarter [25] - The average price per transaction increased by 25% in Q4 2025 compared to the previous year, indicating pricing power for the company's unique product [18] Market Data and Key Metrics Changes - The banking and lending sector continues to grow, with year-over-year growth nearly doubling, while retail saw a decline of 1% [40] - The automotive revenue grew 125% year-over-year, with significant potential for further growth through channel partners [71] Company Strategy and Development Direction - The company aims to build a durable, differentiated, high-margin business by expanding with existing customers and onboarding new ones while maintaining disciplined execution [21] - There is a focus on diversifying into new verticals such as title insurance, automotive, specialty finance, background screening, logistics, and digital account security [18][17] - The company is committed to creating new opportunities for growth and profitability while refining its sales team and channel partner program [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in banking, which is less dependent on interest rates or consumer confidence [18] - The company is well-positioned to capitalize on future opportunities as interest rates decline, which could turn current headwinds into tailwinds [55] - Management highlighted the importance of maintaining expense discipline and expects operating expenses to grow at a slower rate than revenue [38][66] Other Important Information - The company ended the year with $9.6 million in cash and a strong debt-free balance sheet, reflecting strong cash generation from operations [7][35] - The significant decline in software capitalization from over $2 million in 2024 to just $213,000 in 2025 indicates a cleaner financial profile moving forward [36] Q&A Session Summary Question: What was the performance of the bank lending channel and retail channel in Q4? - The banking and lending channel continues to grow, with retail experiencing a seasonal bump but ultimately down 13% year-over-year [40][42] Question: How does the pipeline look for new customers in 2026? - The pipeline appears strong, driven by interest in the new desktop solution and partnerships, particularly with Alloy [43][44] Question: What is the status of the relationship with Ping Identity? - The company needs to improve its channel partnership with Ping Identity to facilitate better collaboration [48] Question: Can you provide growth expectations for 2026? - While the company does not provide formal guidance, there is built-in growth from existing clients, and the focus is on how quickly implementations can occur [63] Question: What metrics can be shared regarding the automotive sector? - Automotive revenue grew 125% year-over-year, with significant potential for further growth through channel partners [71]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 reached a record $9.2 million, up 31% year-over-year, bringing full year 2025 revenue to $32 million, a 27% increase over 2024 [14][18] - Prescription device revenue increased 23% year-over-year to $26 million, driven by growth in gammaCore and Quell products [14][18] - Net loss for 2025 was $14 million or $1.65 per share, compared to a net loss of $11.9 million or $1.59 per share in 2024 [21][22] Business Line Data and Key Metrics Changes - VA hospital system remains the largest customer, with 200 facilities purchasing gammaCore products, up from 170 a year ago [14][15] - General wellness revenue for Q4 reached $1.4 million, representing 31% year-over-year growth, with full year revenue totaling $5.5 million, a 97% increase compared to 2024 [15][16] Market Data and Key Metrics Changes - Approximately 13,400 VA patients received gammaCore devices, representing roughly 2% penetration of the addressable VA headache market [15] - The company is expanding its VA sales presence by adding internal team members and contracted representatives [15] Company Strategy and Development Direction - The company is focused on increasing sales within covered entities such as the VA system and expanding into general wellness with the Truvaga product [8][12] - A leadership transition is underway, with Joshua Lev appointed as interim president and Michael Fox joining as Chief Operating Officer to enhance commercial efforts [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for sustained revenue acceleration and long-term value creation, emphasizing the importance of operational efficiency [12][23] - The company expects full year 2026 revenue to continue growing at approximately 30%, although detailed guidance is not being issued at this time due to the leadership transition [23] Other Important Information - The company is investing in people, marketing, and product development to accelerate growth while maintaining discipline around operating efficiency [17][23] - The Quell Relief product is expected to launch in the first half of 2026, with revenue from this product considered incremental to existing guidance [52] Q&A Session Summary Question: Can you talk about the channels, VA and DTC for both gammaCore and Quell? - Management highlighted the acceleration in the VA channel and the addition of new commercial leadership to drive growth [30][31] Question: Can you discuss OUS channels and expectations for 2026? - The NHS in England remains a key focus for OUS revenue, with ongoing efforts to develop infrastructure in other countries [34][38] Question: Will Michael focus primarily on the VA business while Joshua handles wellness and ex-VA? - Yes, Michael will focus on commercial growth across various channels, while Joshua will manage wellness products [44][45] Question: Is there any adjustment to VA contracts with the onboarding of Michael? - Current VA contracts are expected to remain unchanged, but opportunities for efficiency improvements may be explored [47] Question: Will there be a de-emphasis on the TAC-STIM product after Dan's departure? - No, there is still a robust pipeline for TAC-STIM, and Michael's experience may help accelerate revenue opportunities [49] Question: Will Quell Relief be sold into VA/DOD channels or general wellness? - Quell Relief is an over-the-counter product expected to launch in the first half of 2026, with revenue considered incremental to guidance [52] Question: What are the updates on insurance reimbursement coverage? - The company has made progress with Kaiser, which is seen as a significant opportunity for broader reimbursement adoption [56][58]

Eton Pharmaceuticals (NasdaqGM:ETON) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsDavid Krempa - Chief Business OfficerIpek Erdogan-Trinkaus - Chief Commercial OfficerJames Gruber - CFOSean Brynjelsen - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research Analyst of HealthcareMadison El-Saadi - Healthcare Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity research AnalystOperatorGood afternoon, and welcome to the Eton Pharmaceuticals f ...

Financial Data and Key Metrics Changes - For fiscal 2025, the company achieved net sales of $1 billion and adjusted EBITDA of $63.6 million, reaching the top end of its guidance [4][21] - In Q4, net sales were $236.2 million, down from $275.6 million in the prior year, with a comparable sales decline of 10% [22] - Gross profit for Q4 was $70.9 million, with a gross margin of 30%, compared to 33.6% in the prior year [22] - SG&A expenses decreased by $11.4 million to $62.4 million, representing 26.4% of net sales [22] - The net loss for Q4 was $8.1 million, or $0.08 per share, compared to a net loss of $3 million, or $0.03 per share, in the previous year [23] Business Line Data and Key Metrics Changes - The company saw strength in dresses, with growth for four consecutive quarters, and a positive turnaround in knit tops during the latter half of Q4 [5][6] - Sub-brands generated over $70 million in sales in 2025, with a projected growth of approximately 60% to $110 million in 2026 [10] - The footwear category was successfully reintroduced, with sold-out limited assortments, and is expected to contribute positively in the second half of 2026 [6][12] Market Data and Key Metrics Changes - The company closed 151 stores in fiscal 2025, with an additional 11 closures in Q1 2026, optimizing its store footprint [7][24] - Customer retention rates from closed locations have performed consistently with historical levels, validating the network strategy [24] Company Strategy and Development Direction - The primary focus for 2026 is to accelerate customer file growth through retention, reactivation, and acquisition strategies [6][15] - The company is implementing targeted, segmented marketing to acquire new customers and reactivate lapsed ones, with over 7 million lapsed customers reachable through owned marketing channels [17][18] - The company aims to leverage its omni-channel ecosystem to enhance customer engagement and retention [8][9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged economic pressures affecting customer spending, which has been addressed through the opening price point strategy [34][35] - The company expects to enter 2026 with a stronger operating structure and anticipates capturing an additional $40 million in expense savings from store closures [25][26] - For fiscal 2026, the company projects net sales of $940 million to $960 million and adjusted EBIT of $65 million to $75 million, indicating margin expansion [26] Other Important Information - The company has strategically right-sized its channels and optimized its pricing platforms, entering a phase of maximization and scale [18] - The opening price point strategy now represents approximately 30% of the total assortment and is expected to grow to nearly 40% [14] Q&A Session Summary Question: Insights on sub-brands and their performance - Management expressed satisfaction with the progress of sub-brands, highlighting strong performers and adjusting growth expectations [31][32] Question: Customer retention and reactivation strategies - Management noted that economic pressures were a primary reason for customer lapses and emphasized the effectiveness of the opening price point strategy in reactivating customers [35][36] Question: Sales cadence during the holiday season and tariff impacts - Management reported positive sales momentum in January and acknowledged tariff pressures affecting margins, particularly in the footwear category [42][44] Question: Marketing plans and loyalty program changes - Management discussed a shift in promotional strategies, reducing reliance on Torrid Cash and focusing on price point messaging to drive customer engagement [51][52] Question: Future growth and pricing strategies - Management indicated a pivot towards a more offensive strategy, focusing on refining customer segmentation and promotional efforts to enhance frequency and engagement [62][66]

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported fourth quarter product revenue of $21.3 million, an increase of 83% year-over-year, driven by strong performance from Alkindi Sprinkles and new products Increlex, Galzin, and KHINDIVI [5][38] - The adjusted EBITDA margin improved to 29%, up from 18% in the prior year period, indicating significant progress in profitability [6][45] - GAAP net income for the quarter was $1.5 million, compared to a net loss of $0.6 million in the prior year [46][47] Business Line Data and Key Metrics Changes - The launch of Increlex, Galzin, and KHINDIVI contributed significantly to revenue growth, with both Increlex and Galzin exceeding initial expectations [5][38] - Alkindi Sprinkles continued to perform strongly, contributing to the overall revenue increase [5][38] - The company expects adjusted gross margins to be comfortably above 70% for the full year, with potential to reach between 75% and 80% in the coming years [39][40] Market Data and Key Metrics Changes - The addressable market for DESMODA includes both pediatric and adult patients, expanding the potential patient base significantly beyond initial estimates [10][11] - The company anticipates a peak sales forecast of $30 million to $50 million for DESMODA, with initial demand showing strong traction [10][11] Company Strategy and Development Direction - Eton aims to build the largest rare disease portfolio in the U.S. and has set new long-term goals, including reaching a $200 million revenue run rate by the end of 2027 [32][33] - The company plans to optimize the distribution model for HEMANGEOL to improve operational efficiency and margin performance [20][21] - Eton is focused on maintaining profitability while pursuing growth, with a target of achieving a 50% adjusted EBITDA margin by 2028 [34][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for existing products and the successful integration of new acquisitions, including HEMANGEOL and DESMODA [31][60] - The company expects to generate significant operating cash flow throughout 2026 and beyond, indicating a positive outlook for financial health [48] Other Important Information - Eton's acquisition of HEMANGEOL was completed for $14 million in cash, avoiding dilution or incremental debt, which is expected to enhance earnings [24] - The company is preparing for a pilot initiative targeting adult endocrinologists for DESMODA, assessing the opportunity over the next 90 days [10] Q&A Session Summary Question: Growth assumptions for HEMANGEOL - Management believes that increasing patient adoption will be driven by a zero copay initiative and enhanced awareness efforts [50][51] Question: DESMODA's pace to peak sales - The launch of DESMODA has gone well, with expectations for quicker peak sales compared to previous products due to the specific unmet need it addresses [53][54] Question: Cash flow conversion from EBITDA in 2026 - The company anticipates being firmly in positive operating cash flow territory in 2026, with some timing considerations for supplier commitments [56][57] Question: $200 million run rate by end of 2027 - Management is confident that the existing product portfolio, including HEMANGEOL and DESMODA, will contribute significantly to achieving this goal [59][60]